Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.

March 13, 2026

Vol.52 No.10

By Claire Marie Porter

Cancer Policy

FDA approves leucovorin for cerebral folate deficiency

FDA has approved leucovorin calcium tablets (Wellcovorin), expanding its use for the treatment of cerebral folate deficiency in adult and pediatric patients.

March 13, 2026

Vol.52 No.10

By Claire Marie Porter

Drugs & Targets

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM

FDA has approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

March 06, 2026

Vol.52 No.09

Drugs & Targets

FDA grants tentative approval for Lutetium Lu 177 dotatate

FDA has granted tentative approval for the Abbreviated New Drug Application for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of Lutathera (lutetium Lu 177 dotatate), which is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.

March 06, 2026

Vol.52 No.09

Cancer Policy

FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases

FDA issued draft guidance for sponsors seeking full approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety when randomized controlled trials are not feasible due to small patient populations.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology

Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”

YOU MAY BE INTERESTED IN

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

FDA approves leucovorin for cerebral folate deficiency

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM

FDA grants tentative approval for Lutetium Lu 177 dotatate

FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login